
<p>Infektolog prof. Dr. Janez Tomažič in specialist družinske medicine dr. Aleksander Stepanović pojasnita terapevtsko možnost zdravljenja bolezni covid-19 in svetujeta, kako zdravilo predpisati v ambulanti družinske medicine.</p>


Paxlovid (nirmatrelvir/ritonavir) - nova terapevtska možnost zdravljenja COVID-19

Družinski zdravnik in predpisovanje Paxlovida (nirmatrelvir/ritonavir)


<p>Vsebino izobraževanja si lahko ogledate na spodnji predstavitvi.</p>


<ol>
<li>Editorial. Lancet 2022;399:1753.</li>
<li>Lian J. CID 2020</li>
<li>Slovenska priporočila 2022</li>
<li>Ziemba R et al. MMWR Morb Mortal Wkly Rep. 2021;70:825-829.</li>
<li>Fisher AM et al. Clin Transplant. 2021;35:e14216.</li>
<li>Whitaker HJ et al. Online ahead of print. J Infect. 2022.</li>
<li>Haidar G et al. Clin Infect Dis. 2021;73:e1397-e1401.</li>
<li>Harpaz R et al. JAMA. 2016;316:2547-2448; 2. <a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html">COVID-19 Vaccines for Moderately to Severely Immunocompromised People</a>. Centers for Disease Control and Prevention. Updated September 2, 2021. Accessed October 1, 2021.</li>
<li>Abbasi J. JAMA. 2021;325:2033-2035.</li>
<li>Rincon-Arevalo, Hector, et al. &#8220;Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients.&#8221; Science immunology 6.61 (2021): eabj1031.</li>
<li>Saddiqi HK. J Heart Lung Transpl 2020.</li>
<li>Corti D et al. Cell. 2021;184:3086-3108.</li>
<li>National Institutes of Health. &#8220;<a href="https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf">Coronavirus disease 2019 (COVID-19) treatment guidelines.</a>&#8221; (2020).</li>
<li>Hammond, Jennifer, et al. &#8220;Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.&#8221; New England Journal of Medicine 386.15 (2022): 1397-1408.</li>
<li>Pluskota-Karwatka D, et al. J Pharm Anal 2021;11(4):383-97.</li>
<li>V&#8217;Kovski P, et al. Nat Rev Microbiol 2021;19(3):155-70.</li>
<li>SERIOUS, POTENTIALLY, and OR LIFE THREATENING. &#8220;<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209512lbl.pdf">Highlights of prescribing information.</a>&#8221; interactions 5: 7-2.</li>
<li>Cooper, CL et al. Clin Infect Dis 2003;36(12):1585–92.</li>
<li>Hill A et al. AIDS 2009;23:2237–45.</li>
<li>Owen DR, et al. Science 2021;374(6575):1586–93. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/management-of-drug-interactions-with-nirmatrelvirritonavir-paxlovid</li>
<li>Bhave NM et al, ACC 2022.</li>
<li>Strokovno stališče KO za žilne bolezni, UKC Ljubljana, pripravljeno 6.9.22</li>
<li>Liverpool. <a href="https://www.covid19-druginteractions.org/checker">COVID-19 Drug Interactions iChart</a>.</li>
<li>DSA: <a href="https://www.idsociety.org/globalassets/idsa/practice-guidelines/covid-19/treatment/idsa-paxlovid-drug-interactions-resource-5-6-22-v1.1.pdf">Management of Drug Interactions With Nirmatrelvir/Ritonavir (Paxlovid®): Resource for Clinician</a>.</li>
<li>Hammond, Jennifer, et al. &#8220;Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.&#8221; New England Journal of Medicine 386.15 (2022): 1397-1408.</li>
<li>SMPC: povzetek glavnih značilnosti zdravila Paxlovid, 28. 1. 2022.</li>
<li>Rausch, Jason W., et al. &#8220;Low genetic diversity may be an Achilles heel of SARS-CoV-2.&#8221; Proceedings of the National Academy of Sciences 117.40 (2020): 24614-24616.</li>
<li>Simon-Loiere E. Nature 2022;20.</li>
</ol>


Avtor/ji

Opravite izobraževanje in pridobite kreditne točke

Paxlovid (nirmatrelvir/ritonavir) - nova terapevtska možnost zdravljenja COVID-19

Družinski zdravnik in predpisovanje Paxlovida (nirmatrelvir/ritonavir)

Reference

Uporabite Mediately aplikacijo

Uporabite Mediately aplikacijo